

#### Dr Reddy's Laboratories Ltd.

# USGAAP Financials UNAUDITED FINANCIAL STATEMENTS

Statement of Income	02
Balance Sheet	03
Statement of Cash Flows	04
Indian - US GAAP: Profit Reconciliation	05

#### **USGAAP - Statement of Income**

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share data)

_	(Audited)	(Un-audited) Three months ended December 31,		
_	Year ended			
	March 31, 2001	2000	2001	2001
Revenues:				
Product sales, net of allowances for sales returns (includes				
excise duties of Rs.733,841 for the year ended March 31, 2001 and Rs.139,972 and Rs.188,822 for the three months				
ended December 31, 2000 and 2001 respectively)	Rs.10,974,809	Do 2 562 629	Rs. 4,451,074	US\$ 92,212
License fees	KS. 10,974,009	RS. 2,303,030	124,757	2,585
	10,974,809	2,563,638	4,575,831	94,797
Cost of revenues	5,735,847	1,461,393	1,816,052	37,623
Gross profit	5,238,962	1,102,245	2,759,779	57,174
Operating expenses:				
Selling, general and administrative expenses	2,818,870	663,726	984,686	20,400
Research and development expenses	508,837	109,179	235,763	4,884
Amortisation expenses	482,334	117,264	109,379	2,266
Foreign exchange (gain)/loss	(62,105)	(18,255)	(59,673)	(1,236)
Total operating expenses	3,747,936	871,914	1,270,155	26,314
Operating income	1,491,026	230,331	1,489,624	30,860
Equity in loss of affiliates	(31,520)	(5,643)	(37,133)	(769)
Other (expenses)/income, net	(387,005)	(70,412)	42,405	878
Income/(loss) before income taxes and minority interest	1,072,501	154,276	1,494,896	30,969
Income tax (expense)/benefit	(321,396)	(42,224)	(182,529)	(3,781)
Minority interest	(9,155)	(2,993)	331	7
Net income	Rs.741,950	Rs. 109,059	Rs. 1,312,698	US\$ 27,195
			47.40	
Basic and diluted net income per equity share	11.74	1.73	17.16	0.36
Weighted average number of equity shares used in	00 477 500	00 477 500	76,485,136	70 405 400
computing basic and diluted net income per equity share	63,177,560	63,177,560	70,700,100	76,485,136

See accompanying notes to the consolidated financial statements

## BALANCE SHEET (in thousands, except share data)

	(Audited)	(Un-audited) As of December 31,	
	As of		
	March 31, <b>2001</b>	2001	2001
ASSETS	2001		2001
Current assets:			
Cash and cash equivalents	Rs.478,979	Rs. 4,037,805	US\$ 83,650
Restricted cash	18,670	44,931	931
Accounts receivable, net of allowances	2,379,703	3,921,512	81,241
Inventories	1,919,354	2,641,272	54,719
Deferred income taxes	158,931	168,253	3,486
Due from related parties	23,338	8,587	178
Other current assets	328,796	533,015	11,042
Total current assets	5,307,771	11,355,375	235,247
Property, plant and equipment, net	3,243,706	3,566,868	73,894
Due from related parties	34,523	60,459	1,253
Intangible assets	2,889,373	2,644,746	54,791
Investment securities	21,337	20,000	414
Investment in affiliates	284,970	277,016	5,739
Other assets	101,205	103,712	2,149
Total assets	Rs.11,882,885	Rs. 18,028,176	US\$ 373,486
LIABILITIES AND STOCKHOLDERS' EQUITY  Current liabilities:			
	Do 2 560 005	Do 150 200	1100 2 112
Borrowings from banks	Rs.2,569,095	Rs. 150,280	US\$ 3,113
Current portion of long-term debt	379,515 109	2,960	61
Current portion of capital lease obligations	684,364	1,060,267	21,965
Trade accounts payable  Due to related parties	1,083	1,000,207	21,903
	163,120	179,121	3,711
Taxes payable	383,432	566,330	11,733
Accrued expenses Other current liabilities	331,683	336,966	6,981
Total current liabilities	4,512,401	2,296,991	47,586
	1,003,378	45,299	938
Long-term debt, excluding current portion	69,813	288,382	5,974
Deferred revenue  Deferred income taxes	864,857	762.514	15,797
Other liabilities	175,970	155,742	3,226
	6,626,419	3.548.928	73,522
Total liabilities		3,340,920	75,322
Minority interest	16,002	-	-
Stockholders' equity:			
Equity shares at Rs.5 par value; 100,000,000			
shares authorized; Issued and outstanding; 63,177,560 and 76,515,948 shares as on March			
31, 2001 and December 31, 2001 respectively	315,889	382,580	7,926
Additional paid-in capital	4,296,154	10,146,975	210,213
Retained earnings	627,137	3,947,316	81,776
Equity shares held by a controlled trust: 41,400 shares	(4,882)	(4,882)	(101)
Accumulated other comprehensive income	6,166	7,259	150
Total stockholders' equity	5,240,464	14,479,248	299,964
Total liabilities and stockholders' equity	Rs.11,882,885	Rs. 18,028,176	US\$ 373,486
1. 2		· <del></del> -	

## CASH FLOW STATEMENT (in thousands, except share data)

·		(Un-audited)	
	Three me	onths ended Decem	her 31
•	2000	2001	2001
Cash flows from operating activities:			
Net income/(loss)	Rs 109,059	Rs. 1,312,698	US\$ 27,195
Adjustments to reconcile net income/(loss) to net cash from operating activities:	·		
Deferred tax expense/(benefit)		75,238	1,559
Depreciation and amortization		226,209	4,686
Loss/(gain) on sale of property, plant and equipment		422	9
Provision for doubtful accounts receivable	,	16,189	335
Allowance for sales returns	-,	27,534	570
Inventory write-downs.	,	10,980	227
Deferred revenue		(16,982)	(352)
Equity in loss of affiliates.	-,	37,133	769
Exchange (gain)/loss on remeasurement	•	(8,087)	(168)
Changes in operating assets and liabilities:	2,993	(331)	(7)
Accounts receivable, net of allowances	(113,815)	524,972	10,876
Inventories		(147,767)	(3,061)
Other assets	( , ,	(213,417)	(4,421)
Due to / from related parties		(8,972)	(186)
Trade accounts payable	( - , )	69,357	1,437
Accrued expenses	- ,	127,400	2,639
Taxes payable	,	(75,153)	(1,557)
Other liabilities		(138,636)	(2,872)
Net cash provided by/(used in) operating activities		1,818,787	37,679
Cook flows from investing patients		-	
Cash flows from investing activities:	0.004	(20,004)	(015)
Restricted cash  Expenditure on property, plant and equipment	,	(29,691)	(615)
Proceeds from sale of property, plant and equipment		(273,293) 702	(5,662) 15
Purchase of investment securities		(20,567)	(426)
Net cash used in investing activities		(322,849)	(6,688)
, in the second		(= ,= = /	(-,,
Cash flows from financing activities:			
Proceeds from/(repayments of) borrowing from banks,	470 400	(400.040)	(0.050)
Proceeds from issuance of long-term debt	,	(128,048)	(2,653)
Repayment of long-term debt	-,	2,412	50 (927)
Principal payments under capital lease obligations		(39,942)	(827)
Dividends	( )	(421,313)	(8,728)
Net cash provided by financing activities	(10,110)	(586.891)	(12.159)
The cash provided by infalleding delivered	00,040	(300,031)	(12,100)
Effect of exchange rate changes on cash	(17,528)	32,604	675
Net increase in cash and cash equivalents during the year		941,651	19,508
Cash and cash equivalents at the beginning of the year		3,096,154	64,142
Cash and cash equivalents at the end of the year	Rs.540,386	Rs. 4,037,805	US\$ 83,650
Supplemental disclosures:			
Cash paid for:			
Interest (net of interest capitalized)	Rs. 85,114	Rs. 3,663	US\$ 76
Income taxes	54,800	175,000	3,625
Supplemental schedule of non-cash investing activities:			
Property, plant and equipment purchased on credit			
during the year	6,253	16,949	351
Non cash investing and financial activities:			
Acquisition of minority interest:			
Fair value of assets acquired in acquisitions		14,373	298
Fair value of intangibles acquired		114,071	2,363
Fair value of liabilities assumed in acquisitions		55,627	1,152
Increase in stock holders' equity	-	72,817	1,509

#### PROFIT RECONCILIATION OF INDIAN – US GAAP FOR Q3 FY02

Net Income as per Indian GAAP	Rs. million 1615.31
Deferred Revenue Expenditure charged off as per Indian GAAP	-
Net Income as per Indian GAAP excluding extraordinary item charge off	1615.31
Differences:	
R&D Expenses	2.35
Depreciation & Amortization	89.12
Income Tax	31.01
Sales Recognition	307.07
Consolidation of Subsidiaries	(133.17)
Equity in loss of affiliates /JVs	37.13
Others	(30.90)
Total Differences	302.61
Net Income as per US GAAP	1312.70